Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• treatment against CD is based on the oral administration of benznidazole, an agent, developed in 1971, of controversial effectiveness on chronically ill patients and toxic to adults. So far, conventional pharmacological approaches have failed to offer more effective and less toxic alternatives to

• benznidazole. Nanomedicines reduce toxicity and increase the effectiveness of current oncological therapies. Could nanomedicines improve the treatment of the neglected CD? This question will be addressed in this review, first by critically discussing selected reports on the performance of benznidazole and

• still required regarding a realistic use of nanomedicines effective against CD. Keywords: benznidazole; liposomes; nanocrystals; nanomedicines; nanoparticles; Trypanosoma cruzi; Introduction Nanomedicines are used to solve the problems posed by poor solubility and/or permeability and high toxicity of

Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies

• Giuliana Muraca,
• María Esperanza Ruiz,
• Rocío C. Gambaro,
• Sebastián Scioli-Montoto,
• María Laura Sbaraglini,
• Gisel Padula,
• José Sebastián Cisneros,
• Cecilia Yamil Chain,
• Vera A. Álvarez,
• Cristián Huck-Iriart,
• Guillermo R. Castro,
• María Belén Piñero,
• Matias Ildebrando Marchetto,
• Catalina Alba Soto,
• Germán A. Islan and
• Alan Talevi

Beilstein J. Nanotechnol. 2023, 14, 804–818, doi:10.3762/bjnano.14.66

• Alan Talevi See end of main text. 10.3762/bjnano.14.66 Abstract Chagas disease is a neglected endemic disease prevalent in Latin American countries, affecting around 8 million people. The first-line treatment, benznidazole (BNZ), is effective in the acute stage of the disease but has limited efficacy

• . These results show potential for the development of new nanomedicines against T. cruzi. Keywords: benznidazole; biopharmaceutical study; Chagas disease; nanoparticles; nanostructured lipid carriers; physicochemical characterization; Trypanosoma cruzi; Introduction Chagas disease is a neglected disease

• chronically infected individuals [1][4]. Currently, two drugs have been approved for the treatment of Chagas disease: benznidazole (BNZ) and nifurtimox. The first-line treatment, BNZ, is a nitroimidazole that generates radical intermediates via the reduction of its nitro group, which covalently bind to